Details for Patent: 7,151,106

Title:	Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
Abstract:	The invention relates to a new crystalline form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-- 2-ylamino)phenyl]-benzamide of formula 1, which may be used for example for tumor therapy. ##STR00001##
Inventor(s):	Hayry; Pekka (Helsinki, FI)
Assignee:	Novartis A.G. (Basel, CH)
Filing Date:	Nov 16, 2001
Application Number:	09/991,184
Claims:	1. A method of preventing or treating restenosis comprising administering a therapeutically effective amount of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-- 2-ylamino)pheyl]benzamide to a warm-blooded animal, wherein the 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-- 2-ylamino)pheyl]benzamide is present in free form or in pharmaceutically acceptable salt form. 2. A method of preventing or treating restenosis comprising administering a therapeutically effective amount of the methanesulfonic acid salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-- 2-ylamino)pheyl]benzamide to a warm-blooded animal. 3. A method of preventing or treating restenosis comprising administering a therapeutically effective amount of the .beta.-crystal form of the methanesulfonic acid salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-- 2-ylamino)pheyl]benzamide to a warm-blooded animal. 4. A method of preventing or treating restenosis comprising administering a therapeutically effective amount of the .alpha.-crystal form of the methanesulfonic acid salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3(4-pyridin-3-yl)pyrimidin-2- -ylamino)pheyl]benzamide to a warm-blooded animal. 5. The method of claim 3 wherein the prevention or treatment of restenosis comprises administering a therapeutically effective amount of a crystalline form of the monomethanesulfonic acid addition salt of a compound of formula I, ##STR00004## which is non-hygroscopic in a glass climatic chamber at 25.degree. C. and relative humidities up to and including 93%, to a patient in need thereof.